Key result
Natural compounds may protect cardiomyocytes by countering intracellular AGE-induced protein dysfunction.
Why the study?
The authors examine the role of intracellular advanced glycation end-products in cardiomyocytes as an inducer of non-ischemic cardiovascular disease and evaluate natural compounds that may inhibit them.
Does the accumulation of intracellular advanced glycation end-products induce cardiomyocyte dysfunction, and can natural compounds from traditional medicines prevent this?
Does the accumulation of intracellular advanced glycation end-products induce cardiomyocyte dysfunction, and can natural compounds from traditional medicines prevent this?
Answers are grounded in this paper and cite their sources.
Understanding how specific intracellular AGEs induce non-ischemic cardiomyocyte dysfunction highlights the mechanistic potential of targeted natural compounds as a novel preventive strategy for heart failure.
Cardiomyocyte dysfunction and cardiovascular diseases (CVDs) can be classified as ischemic or non-ischemic. We consider the induction of cardiac tissue dysfunction by intracellular advanced glycation end-products (AGEs) in cardiomyocytes as a novel type of non-ischemic CVD. Various types of AGEs can be generated from saccharides (glucose and fructose) and their intermediate/non-enzymatic reaction byproducts. Recently, certain types of AGEs (Nε-carboxymethyl-lycine [CML], 2-ammnonio-6-[4-(hydroxymetyl)-3-oxidopyridinium-1-yl]-hexanoate-lysine [4-hydroxymethyl-OP-lysine, hydroxymethyl-OP-lysine], and Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine [MG-H1]) were identified and quantified in the ryanodine receptor 2 (RyR2) and F-actin–tropomyosin filament in the cardiomyocytes of mice or patients with diabetes and/or heart failure. Under these conditions, the excessive leakage of Ca2+ from glycated RyR2 and reduced contractile force from glycated F-actin–tropomyosin filaments induce cardiomyocyte dysfunction. CVDs are included in lifestyle-related diseases (LSRDs), which ancient people recognized and prevented using traditional medicines (e.g., Kampo medicines). Various natural compounds, such as quercetin, curcumin, and epigallocatechin-3-gallate, in these drugs can inhibit the generation of intracellular AGEs through mechanisms such as the carbonyl trap effect and glyoxalase 1 activation, potentially preventing CVDs caused by intracellular AGEs, such as CML, hydroxymethyl-OP, and MG-H1. These investigations showed that bioactive herbal extracts obtained from traditional medicine treatments may contain compounds that prevent CVDs.
No takes yet. Share an insight, caveat, or question.
Takata et al. (2024) conducted a review in Cardiomyocyte dysfunction and non-ischemic cardiovascular disease. Advanced glycation end-products (AGEs) was evaluated. Intracellular advanced glycation end-products (AGEs) modify key proteins like RyR2 and F-actin-tropomyosin in cardiomyocytes to induce dysfunction, a process that natural compounds in traditional medicines may inhibit.
Synapse has enriched 10 related papers. Consider them for comparative context: